Amicus Doubles Cash in $57M Offering; Amigal Data in 3Q12
By Jennifer Boggs
Monday, March 5, 2012
Awaiting much-anticipated data from its pivotal Fabry disease program later this year, Amicus Therapeutics Inc. is doubling its cash balance via a $57 million public offering.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.